Clinical characteristics of diabetic ketoacidosis in users and non-users of SGLT2 inhibitors

DKA Study Group of Gyeonin Branch of the Korean Diabetes Association

Research output: Contribution to journalArticle

Abstract

Aim: This study investigated the clinical characteristics of diabetic ketoacidosis (DKA) and compared the DKA characteristics between patients treated with and without SGLT2 inhibitors. Methods: Data were collected from patients aged ≥ 18 years admitted for DKA at nine centres in Korea between September 2014 and April 2017. The electronic medical records of these subjects were retrospectively reviewed. Based on their history of medications taken before admission, subjects were classified as either users or non-users of SGLT2 inhibitors and their clinical characteristics of DKA were compared. Results: During the study, the main subtype of DKA episodes (n = 523) was identified as type 2 diabetes (51%). Average hospitalization duration was 11 days, and average intensive care unit (ICU) time was 2.5 days. The in-hospital mortality rate was 3%, but no users of SGLT2 inhibitors died during DKA treatment. In patients taking SGLT2 inhibitors (n = 15), DKA manifested at 124 days, on average, after starting the inhibitors (range: 7–380 days). Also, SGLT2 inhibitors users had significantly lower plasma glucose levels (413 mg/dL) compared with non-users (554 mg/dL), and longer ICU stays (4 vs. 2 days; P = 0.019). Conclusion: In this report of recent data on the clinical features of DKA in Korea, patients using SGLT2 inhibitors needed longer treatment in ICUs compared with non-users and had lower levels of blood glucose, whereas DKA associated with SGLT2 inhibitors was rare.

Original languageEnglish
JournalDiabetes and Metabolism
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Diabetic Ketoacidosis
Korea
Intensive Care Units
Electronic Health Records
Hospital Mortality
Type 2 Diabetes Mellitus
Blood Glucose
Hospitalization
Glucose
Mortality

Keywords

  • Diabetic ketoacidosis
  • Republic of Korea
  • Sodium–glucose cotransporter-2 inhibitors

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Clinical characteristics of diabetic ketoacidosis in users and non-users of SGLT2 inhibitors. / DKA Study Group of Gyeonin Branch of the Korean Diabetes Association.

In: Diabetes and Metabolism, 01.01.2019.

Research output: Contribution to journalArticle

DKA Study Group of Gyeonin Branch of the Korean Diabetes Association. / Clinical characteristics of diabetic ketoacidosis in users and non-users of SGLT2 inhibitors. In: Diabetes and Metabolism. 2019.
@article{de59077534b3437e9990914921da102f,
title = "Clinical characteristics of diabetic ketoacidosis in users and non-users of SGLT2 inhibitors",
abstract = "Aim: This study investigated the clinical characteristics of diabetic ketoacidosis (DKA) and compared the DKA characteristics between patients treated with and without SGLT2 inhibitors. Methods: Data were collected from patients aged ≥ 18 years admitted for DKA at nine centres in Korea between September 2014 and April 2017. The electronic medical records of these subjects were retrospectively reviewed. Based on their history of medications taken before admission, subjects were classified as either users or non-users of SGLT2 inhibitors and their clinical characteristics of DKA were compared. Results: During the study, the main subtype of DKA episodes (n = 523) was identified as type 2 diabetes (51{\%}). Average hospitalization duration was 11 days, and average intensive care unit (ICU) time was 2.5 days. The in-hospital mortality rate was 3{\%}, but no users of SGLT2 inhibitors died during DKA treatment. In patients taking SGLT2 inhibitors (n = 15), DKA manifested at 124 days, on average, after starting the inhibitors (range: 7–380 days). Also, SGLT2 inhibitors users had significantly lower plasma glucose levels (413 mg/dL) compared with non-users (554 mg/dL), and longer ICU stays (4 vs. 2 days; P = 0.019). Conclusion: In this report of recent data on the clinical features of DKA in Korea, patients using SGLT2 inhibitors needed longer treatment in ICUs compared with non-users and had lower levels of blood glucose, whereas DKA associated with SGLT2 inhibitors was rare.",
keywords = "Diabetic ketoacidosis, Republic of Korea, Sodium–glucose cotransporter-2 inhibitors",
author = "{DKA Study Group of Gyeonin Branch of the Korean Diabetes Association} and Jeon, {J. Y.} and Kim, {S. K.} and Kim, {K. S.} and Song, {S. O.} and Yun, {J. S.} and Kim, {B. Y.} and Kim, {C. H.} and Park, {S. O.} and S. Hong and Seo, {D. H.} and Seo, {Ji A} and Noh, {J. H.} and Kim, {D. J.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.diabet.2019.01.001",
language = "English",
journal = "Diabetes and Metabolism",
issn = "1262-3636",
publisher = "Elsevier Masson",

}

TY - JOUR

T1 - Clinical characteristics of diabetic ketoacidosis in users and non-users of SGLT2 inhibitors

AU - DKA Study Group of Gyeonin Branch of the Korean Diabetes Association

AU - Jeon, J. Y.

AU - Kim, S. K.

AU - Kim, K. S.

AU - Song, S. O.

AU - Yun, J. S.

AU - Kim, B. Y.

AU - Kim, C. H.

AU - Park, S. O.

AU - Hong, S.

AU - Seo, D. H.

AU - Seo, Ji A

AU - Noh, J. H.

AU - Kim, D. J.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Aim: This study investigated the clinical characteristics of diabetic ketoacidosis (DKA) and compared the DKA characteristics between patients treated with and without SGLT2 inhibitors. Methods: Data were collected from patients aged ≥ 18 years admitted for DKA at nine centres in Korea between September 2014 and April 2017. The electronic medical records of these subjects were retrospectively reviewed. Based on their history of medications taken before admission, subjects were classified as either users or non-users of SGLT2 inhibitors and their clinical characteristics of DKA were compared. Results: During the study, the main subtype of DKA episodes (n = 523) was identified as type 2 diabetes (51%). Average hospitalization duration was 11 days, and average intensive care unit (ICU) time was 2.5 days. The in-hospital mortality rate was 3%, but no users of SGLT2 inhibitors died during DKA treatment. In patients taking SGLT2 inhibitors (n = 15), DKA manifested at 124 days, on average, after starting the inhibitors (range: 7–380 days). Also, SGLT2 inhibitors users had significantly lower plasma glucose levels (413 mg/dL) compared with non-users (554 mg/dL), and longer ICU stays (4 vs. 2 days; P = 0.019). Conclusion: In this report of recent data on the clinical features of DKA in Korea, patients using SGLT2 inhibitors needed longer treatment in ICUs compared with non-users and had lower levels of blood glucose, whereas DKA associated with SGLT2 inhibitors was rare.

AB - Aim: This study investigated the clinical characteristics of diabetic ketoacidosis (DKA) and compared the DKA characteristics between patients treated with and without SGLT2 inhibitors. Methods: Data were collected from patients aged ≥ 18 years admitted for DKA at nine centres in Korea between September 2014 and April 2017. The electronic medical records of these subjects were retrospectively reviewed. Based on their history of medications taken before admission, subjects were classified as either users or non-users of SGLT2 inhibitors and their clinical characteristics of DKA were compared. Results: During the study, the main subtype of DKA episodes (n = 523) was identified as type 2 diabetes (51%). Average hospitalization duration was 11 days, and average intensive care unit (ICU) time was 2.5 days. The in-hospital mortality rate was 3%, but no users of SGLT2 inhibitors died during DKA treatment. In patients taking SGLT2 inhibitors (n = 15), DKA manifested at 124 days, on average, after starting the inhibitors (range: 7–380 days). Also, SGLT2 inhibitors users had significantly lower plasma glucose levels (413 mg/dL) compared with non-users (554 mg/dL), and longer ICU stays (4 vs. 2 days; P = 0.019). Conclusion: In this report of recent data on the clinical features of DKA in Korea, patients using SGLT2 inhibitors needed longer treatment in ICUs compared with non-users and had lower levels of blood glucose, whereas DKA associated with SGLT2 inhibitors was rare.

KW - Diabetic ketoacidosis

KW - Republic of Korea

KW - Sodium–glucose cotransporter-2 inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85061455716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061455716&partnerID=8YFLogxK

U2 - 10.1016/j.diabet.2019.01.001

DO - 10.1016/j.diabet.2019.01.001

M3 - Article

JO - Diabetes and Metabolism

JF - Diabetes and Metabolism

SN - 1262-3636

ER -